High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 8, 2013, Pages 1025-1037

  Malfettone, Andrea ^a   Silvestris, Nicola ^a   Saponaro, Concetta ^a   Ranieri, Girolamo ^a   Russo, Antonio ^b   Caruso, Stefano ^b   Popescu, Ondina ^a   Simone, Giovanni ^a   Paradiso, Angelo ^a   Mangia, Anita ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Aggressiveness; Colorectal cancer; Invasiveness; Mast cell; NHERF1; PAR 2; Prognostic factor; Tryptase

Indexed keywords

PHOSPHOPROTEIN; PROTEINASE ACTIVATED RECEPTOR 2; SODIUM HYDROGEN EXCHANGER REGULATORY FACTOR; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR; TRYPTASE;

ADULT; AGED; AGGRESSIVENESS; ARTICLE; BIOLOGICAL MODEL; CELL COUNT; COLORECTAL CANCER; COLORECTAL TUMOR; CYTOPLASM; ENZYMOLOGY; FEMALE; HUMAN; INTESTINE MUCOSA; INVASIVENESS; MALE; MAST CELL; METABOLISM; MIDDLE AGED; NHERF1; PAR-2; PATHOLOGY; PROGNOSIS; PROGNOSTIC FACTOR; VERY ELDERLY;

AGGRESSIVENESS; COLORECTAL CANCER; INVASIVENESS; MAST CELL; NHERF1; PAR-2; PROGNOSTIC FACTOR; TRYPTASE;

ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; COLORECTAL NEOPLASMS; CYTOPLASM; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MAST CELLS; MIDDLE AGED; MODELS, BIOLOGICAL; PHOSPHOPROTEINS; PROGNOSIS; RECEPTOR, PAR-2; SODIUM-HYDROGEN ANTIPORTER; TRYPTASES;

EID: 84888168718     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12073     Document Type: Article

References (53)

1. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30: 1073-81.
2. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010; 28: 4045-51.
3. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29: 1093-102.
4. Huang B, Lei Z, Zhang GM, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008; 112: 1269-79.
5. Yang Z, Zhang B, Li D, et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE. 2010; 5: e8922.
6. Ch'ng S, Wallis RA, Yuan L, et al. Mast cells and cutaneous malignancies. Mod Pathol. 2006; 19: 149-59.
7. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009; 1796: 19-26.
8. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev. 2001; 53: 245-82.
9. MacNaughton WK. Epithelial effects of proteinase-activated receptors in the gastrointestinal tract. Mem Inst Oswaldo Cruz. 2005; 100 (Suppl. 1): 211-5.
10. Darmoul D, Marie JC, Devaud H, et al. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer. 2001; 85: 772-9.
11. Vergnolle N. Clinical relevance of proteinase activated receptors (pars) in the gut. Gut. 2005; 54: 867-74.
12. Schechter NM, Brass LF, Lavker RM, et al. Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. J Cell Physiol. 1998; 176: 365-73.
13. Corvera CU, Dery O, McConalogue K, et al. Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. J Clin Invest. 1997; 100: 1383-93.
14. Yoshii M, Jikuhara A, Mori S, et al. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci. 2005; 98: 450-8.
15. Soreide K, Janssen EA, Korner H, et al. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol. 2006; 209: 147-56.
16. Bellizzi A, Malfettone A, Cardone RA, et al. NHERF1/EBP50 in breast cancer: clinical perspectives. Breast Care. 2010; 5: 86-90.
17. Voltz JW, Weinman EJ, Shenolikar S. Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene. 2001; 20: 6309-14.
18. Hayashi Y, Molina JR, Hamilton SR, et al. NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia. 2010; 12: 1013-22.
19. Mangia A, Saponaro C, Malfettone A, et al. Involvement of nuclear NHERF1 in colorectal cancer progression. Oncol Rep. 2012; 28: 889-94.
20. Malfettone A, Silvestris N, Paradiso A, et al. Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. Exp Mol Pathol. 2012; 92: 296-303.
21. Scott-Conner CE, Christie DW. Cancer staging using the American Joint Committee on Cancer TNM System. J Am Coll Surg. 1995; 181: 182-8.
22. Hu H, Krasinskas A, Willis J. Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. Semin Oncol. 2011; 38: 500-10.
23. Malfettone A, Saponaro C, Paradiso A, et al. Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. BMC Cancer. 2012; 12: 106.
24. Mangia A, Chiriatti A, Bellizzi A, et al. Biological role of NHERF1 protein expression in breast cancer. Histopathology. 2009; 55: 600-8.
25. Mangia A, Malfettone A, Rossi R, et al. Tissue remodelling in breast cancer: human mast cell tryptase as an initiator of myofibroblast differentiation. Histopathology. 2011; 58: 1096-106.
26. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999; 189: 487-95.
27. Tan SY, Fan Y, Luo HS, et al. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005; 11: 1210-4.
28. Syrjanen KJ, Hjelt LH. Tumor-host relationships in colorectal carcinoma. Dis Colon Rectum. 1978; 21: 29-36.
29. Fisher ER, Paik SM, Rockette H, et al. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol. 1989; 20: 159-63.
30. Acikalin MF, Oner U, Topcu I, et al. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis. 2005; 37: 162-9.
31. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2009; 24: 1265-75.
32. Xia Q, Wu XJ, Zhou Q, et al. No relationship between the distribution of mast cells and the survival of stage IIIB colon cancer patients. J Transl Med. 2011; 9: 88.
33. Wu X, Zou Y, He X, et al. Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. Int J Surg Pathol. 2013; 21: 111-20.
34. Kim MS, Chae HJ, Shin TY, et al. Estrogen regulates cytokine release in human mast cells. Immunopharmacol Immunotoxicol. 2001; 23: 495-504.
35. Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 1997; 99: 1313-21.
36. Gailit J, Marchese MJ, Kew RR, et al. The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol. 2001; 117: 1113-9.
37. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996; 3: 895-904.
38. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol. 2008; 19: 52-60.
39. Yano H, Kinuta M, Tateishi H, et al. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer. 1999; 2: 26-32.
40. Elpek GO, Gelen T, Aksoy NH, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol. 2001; 54: 940-4.
41. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007; 7: 800-8.
42. Massi D, Naldini A, Ardinghi C, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol. 2005; 36: 676-85.
43. Darmoul D, Gratio V, Devaud H, et al. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004; 279: 20927-34.
44. Nishibori M. Physiology and pathophysiology of proteinase-activated receptors (PARs): preface. J Pharmacol Sci. 2005; 97: 7.
45. Yada K, Shibata K, Matsumoto T, et al. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol. 2005; 89: 79-85.
46. Caruso R, Pallone F, Fina D, et al. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol. 2006; 169: 268-78.
47. Sanchez-Hernandez PE, Ramirez-Duenas MG, Albarran-Somoza B, et al. Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. Gynecol Oncol. 2008; 108: 19-26.
48. Miyata S, Koshikawa N, Yasumitsu H, et al. Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem. 2000; 275: 4592-8.
49. Ardura JA, Friedman PA. Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacol Rev. 2011; 63: 882-900.
50. Bellizzi A, Mangia A, Malfettone A, et al. Na+/H+ exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour. Histopathology. 2011; 58: 1086-95.
51. Mangia A, Malfettone A, Saponaro C, et al. Human epidermal growth factor receptor 2, Na+/H+ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. Hum Pathol. 2011; 42: 1589-95.
52. Chang JH, Park JM, Kim SW, et al. Expression of protease activated receptor-2 in human colorectal cancer and its association with tumor progression. Dis Colon Rectum. 2010; 53: 1202-8.
53. Li Z, Bian LJ, Li Y, et al. Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract. 2009; 205: 542-50.